O
ver recent years, there has been a sustained shift in recognising the need for robust evidence to inform our surgical practice. In oncology, surgery is critical in early detection and management of precancerous conditions. Indeed, surgery is the modality with the greatest potential for both cure and harm, compared with radiotherapy or drug therapies. One might be forgiven for thinking that cancer research is restricted to new drugs and advances in molecular oncology, but research in surgical oncology is also vital in improving outcomes. Similarly, surgeons are often central in recruitment to the wider portfolio of multidisciplinary cancer trials. One of the challenges for surgical oncology is that it is not recognised as a single unified specialty, in contrast to clinical and medical oncology, reflecting the modalities of radiotherapy and chemotherapy.
In 2012, the National Cancer Research Institute (NCRI) produced a report highlighting approaches needed to grow and sustain critical mass in surgical oncology research (Table 1) .
1 This article sets out some of the recent initiatives in and around surgical oncology, largely initiated in response to the NCRI report.
GROWING RecRUITMeNT
In order to better understand the trends, the National Institute for Health Research (NIHR) Clinical Research Network has flagged which cancer trials are recruited to by surgeons. These trials include not only those where surgery is the primary trial intervention but also multimodality trials where the surgeon leads recruitment. Since 2015, there have been 174 surgical oncology trials open and recruiting, and this has equated to around 1 in every 6 of the cancer patients recruited overall. The number of patients recruited in 2017-2018 maintained the impressive data for the previous year at just under 12,000 ( Figure 1 ). 2017-18 also saw the highest ever number of surgical patients recruited to randomised controlled trials, forming 77% of the surgical oncology portfolio, with 8,863 patients recruited. Of the 126 surgical oncology trials open in 2017-2018, 73% recruited well to time and target, which is the same proportion as for the wider portfolio of cancer studies.
These data disabuse the notion that surgeons do not recruit to trials or that surgical trials usually fail. However, it is clear that the portfolio of trials is unevenly distributed by specialty, with breast surgery, urology and colorectal surgery currently dominating. The challenges are therefore to maintain and further improve this portfolio in other cancer sites as well as giving recognition to those trials recruiting well, perhaps noting previously 'unsung heroes'. Furthermore, it is crucial to ensure that the next generation of surgeons are familiar with trial recruitment as a core clinical role rather than merely the preserve of academic surgeons.
The FUTURE OF SURGERY INITIaTIVe
Following on from its 2012 report, the NCRI jointly led a new surgical oncology initiative, entitled Future of Surgery, with The Royal College of Surgeons of England (RCS). A series of five themed workshops were commissioned (Table 2 ) and applications to chair them were invited. Held in 2016 and 2017 with the aim of developing consensus in these critical areas, the workshops were attended by over 250 stakeholders. The published report highlights suggestions for future trial development as well as methodological issues that are common in surgical oncology. 
NIHR Clinical Research Network
PeerRev recruiting patients to surgical and multidisciplinary cancer trials. Every year, nominations are invited for any organisations or people (eg surgeons, multidisciplinary teams, research teams) who have achieved outstanding recruitment to the NIHR surgical oncology trials portfolio. The award is made on the metrics of trial recruitment in the preceding year while also recognising innovation and context. It includes a financial educational prize and an impressive glass award, both sponsored by Swann-Morton. Details of the CREST awards from the past five years can be found on the NIHR website. 
TOMORROW'S LEADERS WORKshOP
One of the barriers to growing recruitment in surgical oncology trials is the paucity of engagement mandated by the training curriculum. Moreover, for many senior trainees in surgery, there is doubtless still a lack of mentorship or exposure to firms where trial recruitment is routinely integrated into normal clinical care. Substantial progress on this front has already been made through changes within the surgical specialty advisory committee, the RCS surgical trials initiative and surgical trainee collaboratives. 
